Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
FEBS Lett ; 580(24): 5681-9, 2006 Oct 16.
Article in English | MEDLINE | ID: mdl-17011553

ABSTRACT

Label-free detection of molecular interactions has considerable potential in facilitating assay development. When combined with high throughput capability, it may be applied to small molecule screens for drug candidates. Phosphorylation is a key posttranslational process that confers diverse regulation in biological systems involving specific protein-protein interactions recognizing the phosphorylated motifs. Using a resonant waveguide grating biosensor, the Epic mark System, we have developed a generic assay to quantitatively measure phospho-specific interactions between a trafficking signal-phosphorylated SWTY peptide and 14-3-3 proteins or anti-phosphopeptide antibodies. Compared with a solution-based fluorescence anisotropy assay, our results support that the high throughput resonant waveguide grating biosensor system has favorable technical profiles in detecting protein-protein interactions that recognize phosphorylated motifs. Hence it provides a new generic HTS platform for phospho-detection.


Subject(s)
14-3-3 Proteins/immunology , 14-3-3 Proteins/metabolism , Antibodies, Phospho-Specific/immunology , Biosensing Techniques/methods , Molecular Structure , Phosphopeptides/chemistry , Phosphopeptides/metabolism , Phosphorylation , Protein Binding , Sensitivity and Specificity
2.
J Biol Chem ; 280(39): 33687-92, 2005 Sep 30.
Article in English | MEDLINE | ID: mdl-16027164

ABSTRACT

Ntcp is a phosphoprotein, and its translocation by cAMP to the plasma membrane is associated with dephosphorylation. However, the phosphorylation site(s) of Ntcp is not known. Thus, the aim of the present study was to determine the potential Ntcp phosphorylation sites and whether any of these phosphorylation sites is involved in Ntcp translocation. To determine the potential phosphorylation sites, metabolically labeled [32P]Ntcp isolated from hepatocytes was digested with clostripain and then subjected to SDS-PAGE followed by autoradiography. Clostripain digestion resulted in two phosphorylated peptides, and cAMP decreased phosphorylation of one of the peptides (7.8 K(d)), which contains the putative third cytoplasmic loop with three serine (Ser-213, Ser-226, and Ser-227) and two threonine (Thr-219 and Thr-225) residues. To determine whether any one of these serine/threonine residues is phosphorylated and/or is involved in Ntcp translocation, each of these serine/threonine residues were mutated to alanine. HuH-7 cells were transiently transfected with the wild-type and the mutated Ntcps followed by determination of taurocholate uptake and Ntcp expression, translocation and phosphorylation. Mutation of only Ser-226 resulted in 30% decrease in Ntcp phosphorylation and in 2.5 and 3.2-fold increases in taurocholate uptake and Ntcp retention in the plasma membrane, respectively. Cyclic AMP failed to further decrease phosphorylation and increase translocation of S226A-Ntcp. Taken together, these results suggest that the Ser-226 in the third cytoplasmic loop of Ntcp is phosphorylated and cAMP may increase Ntcp translocation to the plasma membrane by dephosphorylating Ntcp at this site.


Subject(s)
Cell Membrane/metabolism , Membrane Transport Proteins/metabolism , Serine/metabolism , Alanine/metabolism , Amino Acid Substitution , Animals , Autoradiography , Binding Sites , Cell Line , Cell Line, Tumor , Cyclic AMP/metabolism , Cysteine Endopeptidases/pharmacology , Electrophoresis, Polyacrylamide Gel , Hepatocytes/chemistry , Humans , Membrane Transport Proteins/chemistry , Membrane Transport Proteins/genetics , Molecular Weight , Organic Anion Transporters, Sodium-Dependent , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Phosphorus Radioisotopes , Point Mutation , Protein Structure, Secondary , Protein Transport , Rats , Serine/chemistry , Symporters , Taurocholic Acid/metabolism , Transfection
3.
J Leukoc Biol ; 78(2): 359-71, 2005 Aug.
Article in English | MEDLINE | ID: mdl-15937142

ABSTRACT

The major histocompatibility complex nonrestricted cytotoxic leukemic T cell line T acute lymphoblastic leukemia (TALL)-104 is being pursued as a therapeutic agent for cancer. However, the receptors and effector mechanisms responsible for its broad tumoricidal function remain undefined. Here, we examined the roles played by natural cytotoxicity receptors (NCR), killer cell immunoglobulin-like receptors, cytolytic granule components, and tumor necrosis factor (TNF) family members in tumor recognition and lysis by TALL-104 cells. The perforin-granzyme pathway, TNF-related apoptosis-inducing ligand (TRAIL), and Fas were each involved in the lysis of particular tumor targets by TALL-104. Furthermore, phorbol 12-myristate 13-acetate/ionomycin treatment induced surface expression of Fas-L and TRAIL. In addition, supernatants from CD3-stimulated TALL-104 cultures exhibited antiproliferative activity, which was blocked 50-90% by anti-TNF-alpha monoclonal antibody (mAb). Although negative for the NCR natural killer (NK)p44, this cell line was found to express NKp46. An anti-NKp46 antibody strongly blocked TALL-104-mediated lysis of certain targets and directly induced cytokine production, granule release, and redirected lysis responses. Anti-NKG2D and anti-2B4 also stimulated redirected cytotoxicity by TALL-104. By contrast, anti-NKG2A mAb did not stain the cells or inhibit killing responses. Alternatively, KIR3DL2 was detected on TALL-104, and expression of its reported ligand, human leukocyte antigen (HLA)-A, on target cells provided protection from cytotoxicity. Thus, NKp46, NKG2D, and 2B4 are activating receptors, and KIR3DL2 is an inhibitory receptor on TALL-104. The data demonstrate the ability of TALL-104 cells to recognize a wide variety of tumors with NK cell receptors and kill them with a broad arsenal of cytolytic effector mechanisms, including cytolytic granules and TNF family ligands.


Subject(s)
Cytotoxicity, Immunologic/immunology , Killer Cells, Natural/immunology , Lymphocyte Activation/immunology , Signal Transduction/immunology , T-Lymphocytes, Cytotoxic/immunology , Adoptive Transfer , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacology , Antigens, CD/immunology , Apoptosis Regulatory Proteins , CD3 Complex/immunology , Carcinogens/pharmacology , Cell Degranulation/immunology , Cytotoxicity, Immunologic/drug effects , Fas Ligand Protein , Histocompatibility Antigens Class I/immunology , Humans , Immediate-Early Proteins/immunology , Ionomycin/pharmacology , Ionophores/pharmacology , Jurkat Cells , Lymphocyte Activation/drug effects , Membrane Glycoproteins/immunology , Monomeric GTP-Binding Proteins/immunology , NK Cell Lectin-Like Receptor Subfamily C , NK Cell Lectin-Like Receptor Subfamily K , Natural Cytotoxicity Triggering Receptor 1 , Neoplasms/immunology , Neoplasms/therapy , Receptors, Immunologic/immunology , Receptors, KIR , Receptors, KIR3DL2 , Receptors, Natural Killer Cell , Signal Transduction/drug effects , Signaling Lymphocytic Activation Molecule Family , T-Lymphocytes, Cytotoxic/cytology , TNF-Related Apoptosis-Inducing Ligand , Tetradecanoylphorbol Acetate/pharmacology , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factors/immunology , U937 Cells
4.
Cancer Gene Ther ; 10(12): 870-8, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14712313

ABSTRACT

Data presented here demonstrate that vaccine-induced CD8(+) T cells can eliminate their specific tumor-target with a two-staged attack. First, they release interferon-gamma that results in growth arrest of the tumor cells via induction of antiangiogenic mediators. Then, during the latter stages of the immune response, CD8(+) effector T cells eradicate the remaining tumor cells through perforin-mediated lysis. A combination of these two mechanisms is highly effective in the described model, while either pathway alone fails to completely achieve tumor rejection.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Cancer Vaccines/immunology , Interferon-gamma/metabolism , Lung Neoplasms/therapy , Adenoviridae , Animals , CD8-Positive T-Lymphocytes/physiology , Cancer Vaccines/pharmacology , Cell Division/drug effects , Humans , Interferon-gamma/pharmacology , Lung Neoplasms/veterinary , Membrane Glycoproteins/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Neoplasms, Experimental , Neovascularization, Pathologic , Perforin , Pore Forming Cytotoxic Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...